Trial
NCT04569461
Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Duke University
Collaborators
Merck Sharp & Dohme LLC
Condition
Prostate Cancer
Intervention
pembrolizumab
Why stopped
Discontinuation of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-04